Matching-Adjusted Indirect Comparison of Gecacitinib Monotherapy versus Ruxolitinib Monotherapy and Pelabresib-Ruxolitinib Combination in JAK Inhibitor-Naive Myelofibrosis Patients

Clinical Lymphoma, Myeloma & Leukemia · Elsevier

The publisher did not provide an abstract — full text is available via the link below.

Read at publisher →

Similar articles